SCHEMBL2115704

SCHEMBL2115704

CC(=O)N1CCN(c2nc3ccccc3cc2C(C)N)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 2/20 0.49
PIK3CD O00329 2/20 0.48
PDE10A Q9Y233 3/20 0.46
GBA1 P04062 1/20 0.44
NPY5R Q15761 1/20 0.43
SMO Q99835 1/20 0.43
P2RX3 P56373 3/20 0.42
CYP2C9 P11712 2/20 0.42
ALDH1A1 P00352 3/20 0.42
TSHR P16473 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KDM4E B2RXH2 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MAPT P10636 1/20 0.41
BLM P54132 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2115701 1.00 NCF1 (0.49) NCF1PIK3CDPDE10AGBA1NPY5R
SCHEMBL2115753 0.85 AKT1 (0.41) NCF1PIK3CDSMN1; SMN2KDM4EMAPT
SCHEMBL717258 0.82 PIK3CD (0.53) NCF1PIK3CDNPY5RALDH1A1TSHR
SCHEMBL717259 0.82 PIK3CD (0.53) NCF1PIK3CDNPY5RALDH1A1TSHR
SCHEMBL9165 0.81 PIK3CD (0.44) PIK3CDCYP2C9ALDH1A1TSHRSMN1; SMN2
SCHEMBL715606 0.78 CNR2 (0.41) NCF1PIK3CDPDE10AALDH1A1KDM4E
SCHEMBL715605 0.78 CNR2 (0.41) NCF1PIK3CDPDE10AALDH1A1KDM4E
SCHEMBL2113480 0.77 NCF1 (0.38) NCF1PIK3CDGBA1SMO
SCHEMBL2113484 0.77 NCF1 (0.38) NCF1PIK3CDGBA1SMO
SCHEMBL2113713 0.76 OPRK1 (0.38) NCF1PIK3CDNPY5RALDH1A1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095005-A1 Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors UCB PHARMA S.A. (BE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095005-A1 Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors PI4KA, PDPK1, PIK3CA NCF1 2116/4885PIK3CD 6/4885PDE10A 1182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.